GTC Biotherapeutics to Announce Second Quarter 2008 Earnings on Thursday, August...

GTC Biotherapeutics to Announce Second Quarter 2008 Earnings on Thursday, August 7, 2008

FRAMINGHAM, Mass.--(Business Wire)--
GTC Biotherapeutics, Inc. (Nasdaq: GTCB) ("GTC") will release its
second quarter 2008 financial results on Thursday, August 7, 2008
followed by a webcast conference call starting at 10:00 a.m. Eastern
Time. You may access the live Internet broadcast or the subsequent
archived webcast on GTC's website at http://www.gtc-bio.com, or access
the conference call as follows:

Live Call -- In the United States, dial 1-877-391-6849

Outside the United States, dial 617-597-9298

Reference call ID: when prompted 69521428

Audio Archive -- In the United States, dial 888-286-8010

Outside the United States, dial 617-801-6888

Reference call ID: when prompted 53798560

Participants may pre-register for the call at:

https://www.theconferencingservice.com/prereg/
key.process?key=PVYTCC4V4 (Due to its length, this URL may need to be
copied/pasted into your Internet browser's address field. Remove the
extra space if one exists.)

Pre-registrants will be issued a pin number to use when dialing
into the live call which will provide quick access to the conference
by bypassing the operator upon connection.

NOTE: the audio archive replay of the call will be available one
hour following the end of the call and will be accessible until August
14, 2008.

The earnings webcast is also being distributed over CCBN's
Investor Distribution Network to both institutional and individual
investors. Individual investors can listen to the call through CCBN's
individual investor center at www.earnings.com or by visiting any of
the investor sites in CCBN's Individual Investor Network.
Institutional investors can access the call via CCBN's
password-protected event management site, StreetEvents
(www.streetevents.com).

About GTC Biotherapeutics

GTC Biotherapeutics develops, supplies, and commercializes
therapeutic proteins produced through transgenic animal technology.
ATryn(R), GTC's recombinant human antithrombin, has been approved for
use in Europe and has begun the review process in the United States
under a rolling Biologics License Application. In addition to
ATryn(R), GTC is developing a portfolio of recombinant human plasma
proteins with known therapeutic properties. These proteins include
recombinant forms of human coagulation factors VIIa and IX, which are
used for the treatment of hemophilia, and alpha-1 antitrypsin. GTC
also has a monoclonal antibody portfolio that includes a monoclonal
antibody to CD20 and a monoclonal antibody to CD137. GTC's
intellectual property includes a patent in the United States through
2021 for the production of any therapeutic protein in the milk of any
transgenic mammal. GTC's transgenic production platform is
particularly well suited to enabling cost effective development of
proteins that are difficult to express in traditional recombinant
production systems as well as proteins that are required in large
volumes. Additional information is available on the GTC web site,
http://www.gtc-bio.com.

GTC Biotherapeutics, Inc.
Thomas E. Newberry, 508-370-5374
Vice President, Corporate Communications and
Government Relations
tom.newberry@gtc-bio.com

Copyright Business Wire 2008